3Qiang Sun, et al. , Pharmaceutical Policy in China, ' Health Affairs' ,2008,27 (4), pp1042 - 1050.
4Danzon, P. , et al. Productivity in Pharmaceutical - biotechnology R&D : the Role of Experience and Alliances. Journal of Health E- conomics,2005,24(2) :317 - 339.
5ITA. Pharmaceutical Price Controls in OECD Countries: Implications for US Consumers, Pricing, Research and Development and Innovation. U. S. Department of Commerce, International Trade Administration. 2004.
6Abdulkadir Civan and Michael T. Maloney, The Effect of Price on Pharmaceutical R&D. The B. E. Journal of Economic Analysis&Policy, 2009, 9 ( 1 ) : 1 - 22.
7Abbott, T. A. and Vernon, J. The Cost of US Pharmaceutical Price Reduction: A Financial Simulation Model of R&D, NBER Working Paper,2005, No. 11114.
8Joseph Golec, Shantaram Hegde, and John A. Vernon. Pharmaceutical R&D Spending and Threats of Price Regulation, Journal of Financial and Quantitative Analysis ,2010,45 ( 1 ) :239 -264.
9Kurt R. Brekke, Ingrid Konigbauer and Odd Rune Straume. Reference Pricing of Pharmaceuticals, Journal of Health Economics, 2007, (26) :613 - 642.
10D. Bardey,A. Bommier and B. Jullien. Retail Price Regulation and Innovation: Referrence Pricing in the Pharmaceutical Indus- try. Journal of Health Economics ,2010, (29) : ,303 -316.
